Madrigal Pharmaceuticals earnings were -$465.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest MDGL earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$59.4M, down 44.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MDGL reported annual earnings of -$465.9M, with 24.7% growth. The next MDGL earnings date is May 5, 2025.
Madrigal Pharmaceuticals Earnings Reports & History FAQ
What were Madrigal Pharmaceuticals's earnings last quarter?
On MDGL's earnings call on Invalid Date, Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q4 2024 earnings per share (EPS) of -$2.59, up 54.72% year over year. Total MDGL earnings for the quarter were -$59.42 million. In the same quarter last year, Madrigal Pharmaceuticals's earnings per share (EPS) was -$5.72.
When does Madrigal Pharmaceuticals report earnings?
The next MDGL earnings date is Invalid Date. Add MDGL to your watchlist to be reminded of Madrigal Pharmaceuticals's next earnings date.
Is Madrigal Pharmaceuticals profitable or losing money?
As of the last Madrigal Pharmaceuticals earnings report, Madrigal Pharmaceuticals is currently losing money. Madrigal Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$465.89 million, a 24.69% increase year over year.
What was MDGL's earnings growth in the past year?
As of Madrigal Pharmaceuticals's earnings date in Invalid Date, Madrigal Pharmaceuticals's earnings has grown year over year. MDGL earnings in the past year totalled -$465.89 million.
What are Madrigal Pharmaceuticals's earnings expectations?
The current EPS estimate for Madrigal Pharmaceuticals's earnings report in Invalid Date is -$6.28.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.